Clinical Trials
18 trialsNCT07120607 2025-08-13
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
Anhui Provincial Hospital
Phase 1 Not yet recruiting
NCT05477589 2024-12-19
SCRIPT-AML
Vastra Gotaland Region
Phase 3 Recruiting
NCT06160362 2023-12-07
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Henan Cancer Hospital
Phase NA Unknown
NCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
NCT06056752 2023-10-24
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Anhui Provincial Hospital
Phase 1 Recruiting
NCT05755854 2023-09-22
Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
Anhui Provincial Hospital
Phase 1 Unknown
NCT03166397 2023-01-26
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Sheba Medical Center
Phase 2 Unknown
NCT05649618 2022-12-14
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
Fujian Cancer Hospital
Phase EARLY_PHASE1 Unknown
NCT05648994 2022-12-13
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
Fujian Cancer Hospital
Phase EARLY_PHASE1 Unknown
NCT05640713 2022-12-07
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Henan Cancer Hospital
Phase 1 Unknown
NCT05528887 2022-09-06
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase 1 Recruiting
NCT03648697 2020-08-11
EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC
Fujian Cancer Hospital
Phase 2 Unknown
NCT03412526 2019-04-04
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian
Sheba Medical Center
Phase 2 Unknown
NCT02924753 2017-12-29
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Henan Cancer Hospital
Phase 1 Unknown
NCT03322735 2017-12-29
Study of BCMA CAR-T in Multiple Myeloma
Henan Cancer Hospital
Phase 1/2 Unknown
NCT03263208 2017-10-20
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Henan Cancer Hospital
Phase 1/2 Unknown
NCT03101709 2017-04-05
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Henan Cancer Hospital
Phase 1 Unknown
NCT02275663 2015-01-06
Azacytidine Plus FLAG for Relapsed or Refractory AML
King Fahad Medical City
Phase 2 Unknown